Frontiers in Anti-Cancer Drug Discovery
View Sample
To Avail the Discount Please Click Below.
DEAL OF THE DAY:   US $79.2US $9920%

Editors: Atta-ur-Rahman , M. Iqbal Choudhary

Frontiers in Anti-Cancer Drug Discovery

Volume 4

eBook: US $99 Special Offer (PDF + Printed Copy): US $177
Printed Copy: US $128
Library License: US $396
ISSN: 2451-8395 (Print)
ISSN: 1879-6656 (Online)
ISBN: 978-1-60805-923-2 (Print)
ISBN: 978-1-60805-922-5 (Online)
Year of Publication: 2014
DOI: 10.2174/9781608592251140401

Introduction

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading for all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Indexed in: EMBASE, EBSCO, Ulrich's Periodicals Directory.

Preface

- Pp. i-ii (2)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

List of Contributors

- Pp. iii-vi (4)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

Substance P, the NK-1 Receptor and NK-1 Receptor Antagonists in Cancer Treatment

- Pp. 3-38 (36)
Miguel Muñoz, Rafael Coveñas
View Abstract

Molecular Targeted Drugs under Investigation in Hepatocellular Carcinoma

- Pp. 39-87 (49)
Mohamed Bouattour, Johanna Wassermann
View Abstract

Ruthenium Compounds Targeting Cancer Therapy

- Pp. 88-156 (69)
Denise de Oliveira Silva
View Abstract

Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy

- Pp. 157-228 (72)
Teruhiko Fujii, Keisuke Miwa, Tomoyuki Ushijima, Mototsugu Matsunaga, Masaru Fukahori, Kotaro Yuge, Uhi Toh, Nobutaka Iwakuma, Ryuji Takahashi, Hiroki Takahashi, Miki Takenaka, Mai Mishima, Yoshito Akagi, Masayoshi Kage, Shino Nakagawa, Maki Tanaka
View Abstract

Purinergic Modulation and CD39/ENTPD1 in Cancer

- Pp. 229-292 (64)
Lili Feng, Elliot B. Tapper, Xiaofeng Sun, Marina Gehring, Simon C. Robson, Yan Wu
View Abstract

HER2 Targeted Monoclonal Antibodies and Tyrosine Kinase Inhibitors

- Pp. 293-382 (90)
Neil A. O`Brien, Alexandra Canonici, Karen Howe, Martina S.J. McDermott, Denis M. Collins, Brigid C. Browne, John Crown, Norma O`Donovan
View Abstract

Index

- Pp. 383-405 (23)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free